Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 6/20 | 0.45 |
| ▸ | PPP5C | P53041 | 1/20 | 0.37 |
| ▸ | DNTT | P04053 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | THRA | P10827 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | POLA1 | P09884 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2017266 | 0.84 | GBA1 (0.47) | GBA1PPP5C | |
| SCHEMBL15470821 | 0.77 | GBA1 (0.48) | GBA1PPP5CTSHRALDH1A1LMNA | |
| SCHEMBL19401348 | 0.76 | CHRNB2 (0.42) | PPP5CDNTTCHRNB2CHRNB4CHRNA3 | |
| SCHEMBL533902 | 0.74 | GBA1 (0.50) | GBA1PPP5CTHRB | |
| SCHEMBL13165909 | 0.74 | GBA1 (0.46) | GBA1PPP5CTSHRALDH1A1 | |
| SCHEMBL19549582 | 0.74 | GBA1 (0.46) | GBA1PPP5CTSHRALDH1A1LMNA | |
| SCHEMBL2019586 | 0.73 | SPHK1 (0.41) | EPHX1LMNATHRATHRB | |
| SCHEMBL9475595 | 0.73 | POLB (0.42) | GBA1PPP5CDNTTEPHX1TSHR | |
| SCHEMBL19549635 | 0.71 | GBA1 (0.46) | GBA1TSHRALDH1A1 | |
| SCHEMBL1297968 | 0.71 | NAAA (0.52) | EPHX1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10919928-B2 | Oligonucleotide production method, and nucleoside, nucleotide, or oligonucleotide | AJINOMOTO CO., INC. (JP) | 2021-02-16 | — | — | US | disclosed |
| US-10464966-B2 | Precipitation promoter and precipitation method in which same is used | AJINOMOTO CO., INC. (JP) | 2019-11-05 | — | — | US | disclosed |
| EP-3398955-A1 | OLIGONUCLEOTIDE PRODUCTION METHOD, AND NUCLEOSIDE, NUCLEOTIDE, OR OLIGONUCLEOTIDE | AJINOMOTO CO., INC. (JP) | 2018-11-07 | — | — | EP | disclosed |
| US-20180282365-A1 | OLIGONUCLEOTIDE PRODUCTION METHOD, AND NUCLEOSIDE, NUCLEOTIDE, OR OLIGONUCLEOTIDE | AJINOMOTO CO., INC. (JP) | 2018-10-04 | — | — | US | disclosed |
| US-20170320904-A1 | PRECIPITATION PROMOTER AND PRECIPITATION METHOD IN WHICH SAME IS USED | AJINOMOTO CO., INC. (JP) | 2017-11-09 | — | — | US | disclosed |
| US-20170320904-A1 | PRECIPITATION PROMOTER AND PRECIPITATION METHOD IN WHICH SAME IS USED | AJINOMOTO CO., INC. (JP) | 2017-11-09 | — | — | US | disclosed |
| US-9206230-B2 | Benzylic compound | AJINOMOTO CO., INC. (JP) | 2015-12-08 | — | — | US | disclosed |
| US-20140371424-A1 | BENZYLIC COMPOUND | AJINOMOTO CO., INC. (JP) | 2014-12-18 | — | — | US | disclosed |
| US-8859732-B2 | Benzylic compound | AJINOMOTO CO., INC. (JP) | 2014-10-14 | — | — | US | disclosed |
| EP-2518041-A1 | BENZYL COMPOUND | Ajinomoto Co., Inc. (JP) | 2012-10-31 | — | — | EP | disclosed |
| US-20110160433-A1 | BENZYLIC COMPOUND | AJINOMOTO CO., INC. (JP) | 2011-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160433-A1 | BENZYLIC COMPOUND | VIP, NGLY1, FURIN | GBA1 844/4885PPP5C 4416/4885DNTT 1618/4885 |
| US-20140371424-A1 | BENZYLIC COMPOUND | VIP, NGLY1, FURIN | GBA1 844/4885PPP5C 4416/4885DNTT 1618/4885 |
| US-20180282365-A1 | OLIGONUCLEOTIDE PRODUCTION METHOD, AND NUCLEOSIDE, NUCLEOTIDE, OR OLIGONUCLEOTIDE | NUDT1, RNGTT, POLN | GBA1 3057/4885PPP5C 900/4885DNTT 30/4885 |
| US-20170320904-A1 | PRECIPITATION PROMOTER AND PRECIPITATION METHOD IN WHICH SAME IS USED | SP1, MED25, CTCF | GBA1 3924/4885PPP5C 2073/4885DNTT 802/4885 |
| US-10919928-B2 | Oligonucleotide production method, and nucleoside, nucleotide, or oligonucleotide | POLL, POLM, NUDT1 | GBA1 1539/4885PPP5C 1893/4885DNTT 270/4885 |
| US-10464966-B2 | Precipitation promoter and precipitation method in which same is used | SP1, MED25, CTCF | GBA1 3924/4885PPP5C 2073/4885DNTT 802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.